185 related articles for article (PubMed ID: 35411095)
1. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
Bodaar K; Yamagata N; Barthe A; Landrigan J; Chonghaile TN; Burns M; Stevenson KE; Devidas M; Loh ML; Hunger SP; Wood B; Silverman LB; Teachey DT; Meijerink JP; Letai A; Gutierrez A
Leukemia; 2022 Jun; 36(6):1499-1507. PubMed ID: 35411095
[TBL] [Abstract][Full Text] [Related]
2. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
3. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
Yuan S; Wang X; Hou S; Guo T; Lan Y; Yang S; Zhao F; Gao J; Wang Y; Chu Y; Shi J; Cheng T; Yuan W
Leukemia; 2022 Feb; 36(2):370-382. PubMed ID: 34465864
[TBL] [Abstract][Full Text] [Related]
4. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD
Leukemia; 2018 Mar; 32(3):788-800. PubMed ID: 28852199
[TBL] [Abstract][Full Text] [Related]
5. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
[TBL] [Abstract][Full Text] [Related]
6. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
7. Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
Broux M; Prieto C; Demeyer S; Vanden Bempt M; Alberti-Servera L; Lodewijckx I; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; de Bock CE; Cools J
Blood; 2019 Oct; 134(16):1323-1336. PubMed ID: 31492675
[TBL] [Abstract][Full Text] [Related]
8. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract][Full Text] [Related]
9. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
10. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.
Bains T; Heinrich MC; Loriaux MM; Beadling C; Nelson D; Warrick A; Neff TL; Tyner JW; Dunlap J; Corless CL; Fan G
Leukemia; 2012 Sep; 26(9):2144-6. PubMed ID: 22425895
[No Abstract] [Full Text] [Related]
11. Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient.
Kawashima-Goto S; Imamura T; Seki M; Kato M; Yoshida K; Sugimoto A; Kaneda D; Fujiki A; Miyachi M; Nakatani T; Osone S; Ishida H; Taki T; Takita J; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Hosoi H
Int J Hematol; 2015 Apr; 101(4):411-6. PubMed ID: 25430085
[TBL] [Abstract][Full Text] [Related]
12. Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
Spinella JF; Cassart P; Richer C; Saillour V; Ouimet M; Langlois S; St-Onge P; Sontag T; Healy J; Minden MD; Sinnett D
Oncotarget; 2016 Oct; 7(40):65485-65503. PubMed ID: 27602765
[TBL] [Abstract][Full Text] [Related]
13. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
14. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract][Full Text] [Related]
15. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
16. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
Chonghaile TN; Roderick JE; Glenfield C; Ryan J; Sallan SE; Silverman LB; Loh ML; Hunger SP; Wood B; DeAngelo DJ; Stone R; Harris M; Gutierrez A; Kelliher MA; Letai A
Cancer Discov; 2014 Sep; 4(9):1074-87. PubMed ID: 24994123
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
Akahane K; Sanda T; Mansour MR; Radimerski T; DeAngelo DJ; Weinstock DM; Look AT
Leukemia; 2016 Jan; 30(1):219-28. PubMed ID: 26265185
[TBL] [Abstract][Full Text] [Related]
18. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract][Full Text] [Related]
19. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
Ariës IM; Bodaar K; Karim SA; Chonghaile TN; Hinze L; Burns MA; Pfirrmann M; Degar J; Landrigan JT; Balbach S; Peirs S; Menten B; Isenhart R; Stevenson KE; Neuberg DS; Devidas M; Loh ML; Hunger SP; Teachey DT; Rabin KR; Winter SS; Dunsmore KP; Wood BL; Silverman LB; Sallan SE; Van Vlierberghe P; Orkin SH; Knoechel B; Letai AG; Gutierrez A
J Exp Med; 2018 Dec; 215(12):3094-3114. PubMed ID: 30404791
[TBL] [Abstract][Full Text] [Related]
20. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]